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Abstract: Background: Both neutrophil to lymphocyte ratio (NLR) and platelet to lymphocyte ratio (PLR) are cost-
effective and readily available biomarkers. An increment in either NLR or PLR is an indicative of a prolonged chronic 
inflammatory condition and increased host inflammatory response. Iron deficiency anemia (IDA) is frequently associated 
in chronic disorders.  
Aims: We decided to investigate whether the efficient treatment of IDA should affect NLR and/or PLR values in an adult 
population with IDA.  
Methods: This was a retrospective (case-series) observational study conducted at an adult Hematology clinic in Turkey. 
Patients were ≥ 18 years-old, with IDA defined according to the World Health Organisation criteria. The hematological 
parameters, NLR, and PLR levels were noted before and after oral iron (Fe+2) repletion treatment. 
Results: A total of 200 patients with IDA (median age 44 years, IQR 32-52 years, women 91%) were included. NLR 
values did not differ significantly in terms of IDA treatment (2.07 vs. 2.01, p= .558). PLR levels were significantly 
decreased after IDA treatment (170.63 vs. 140.32, p< .001). The NLR and PLR were positively correlated (p= .01). A 
low-unremarkable inverse correlation between NLR, and serum iron levels (p= .024) and Tfsat (p= .038) was observed; a 
similar negative correlation was also observed between PLR, and serum iron (p= .002) and Tfsat (p= .013) levels.  
Conclusion: The treatment of IDA did not affect NLR, whereas it was associated with significant decrease in PLR. The 
NLR and PLR were positively correlated. However, both the NLR and PLR were inversely correlated with serum iron and 
Tfsat levels.  
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INTRODUCTION 
Anemia is a widespread public health problem and 
is defined as a low hemoglobin concentration with 
respect to normal cut-off values. Global anemia 
prevalance in 2010 was 32.9% [1]. Iron deficiency 
affects more than 2 billion people worlwide, and iron 
deficiency anemia (IDA) remains to be the top cause of 
anemia [2].  
Neutrophil to lymphocyte ratio (NLR), calculated 
from complete blood count with differential, is a readily 
available and inexpensive marker of inflammation in 
ischaemic heart diseases [3], and even in different 
types of solid tumors [4]. Similarly, platelet to 
lymphocyte ratio (PLR) is a cost-effective and 
inexpensive inflammatory biomarker with independent 
prognostic value in solid tumors [5].  
To the best of our knowledge, there is no published 
study about the effects of IDA treatment on NLR or 
PLR. Therefore, the aim of the current study was to  
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define the alterations in NLR and/or PLR before and 
after the treatment of IDA in a Turkish adult population. 
MATERIALS AND METHODS 
Between January 2014 and July 2014, a total of 200 
patients with IDA, 182 female (91%) and 18 male, were 
enrolled to this study. The study protocol was approved 
by the local ethics commitee (Date: 24.03.2015, 
Desicion Number: 04).  
Hemoglobin levels of <13 g/dL in men, and <12 
g/dL in women have been used to define anemia [6]. 
IDA was defined as: ferritin level <15 ng/mL (normal 
range: 20-300 ng/mL), transferrin saturation <15%, and 
mean corpuscular volume <80 fL. Patients with the 
following conditions were excluded from the study: age 
of <18 years, other nutritional anemias (vitamin B12, 
folate), inherited or acquired red cell disorders 
(haemoglobinopathies), acute or chronic infections 
(malaria, tuberculosis, HIV), known malignancies or 
chronic diseases (chronic renal or liver disease, severe 
cardiac or respiratory disease), pregnancy, alcoholism, 
and gastric surgery.  
Treatment protocole, contained 2 x 100 mg/day 
ferrous (Fe+2) glycine sulfate complex perorally until the 
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hematological parameters normalised and serum 
ferritin ≥ 40 ng/mL. Blood samples for complete blood 
count and biochemical analyses were collected before 
and after the treatment protocole for all patients. All 
blood samples were drawn in the fasting state. Data on 
blood cell counts and iron status were extracted in a 
retrospective fashion from the electronic medical 
records database.  
The NLR was defined as the ratio of absolute 
neutrophil count divided by the absolute lymphocyte 
count, and PLR was defined as the ratio of platelet 
count divided by the absolute lymphocyte count. 
STATISTICAL ANALYSIS 
Statistical analyses were performed using the 
Statistical Package for the Social Sciences (SPSS) 
software version 20. The variables were investigated 
using visual (histograms, probability plots) and 
analytical methods (Kolmogorov-Smirnov/Shapiro-
Wilk’s test) to determine whether or not they are 
normally distributed. Descriptive analyses were 
presented using medians and interquartile range (IQR) 
for the non-normally distributed variables. The 
Wilcoxon test was used to compare the non-normally 
distributed numeric variables before and after the 
treatment of IDA. While investigating the associations 
between non-normally distributed variables, the 
correlation coefficients and their significance were 
calculated using the Spearman test. A 5% type-I error 
level was used to infer statistical significance. A value 
of less than .05 was considered to show a statistically 
significant result.  
RESULTS 
1. Clinical Characteristics 
Ninety-one percent (n= 182) of the patients were 
female. Median age was 44 (min-max: 19-93) years. 
Median follow-up of the patients was 63 [Interquartile 
Range (IQR): 36-137] days.  
Table 1: The Comparison of Hematologic Parameters, Neutrophil/Lymphocyte Ratio (NLR), and Platelet/Lymphocyte 
Ratio (PLR) in Patients with Iron Deficiency Anemia (IDA) before and after Oral Iron Repletion Treatment 
Hematologic Parameters Reference Range Before Treatment [Median (IQR)] After Treatment [Median (IQR)] p 
Hemoglobin (g/dL) 11.1-17.1 10.50 (9.10-11.43) 12.70 (11.90-13.40) < .001 
Hematocrit (%) 33-57 33.20 (29.50-35.00) 38.70 (36.75-40.70) < .001 
MCV (fL) 78-100 76.00 (68.15-80.00) 84.00 (78.00-88.00) < .001 
RDW (%) 12-15 16.75 (14.60-19.30) 17.55 (15.20-22.60) < .001 
MCH (pg) 24-31 23.60 (20.55-26.35) 27.25 (24.90-29.30) < .001 
MCHC (g/dL) 28-34 31.30 (30.02-32.40) 32.51 (31.76-33.38) < .001 
WBC (x 109/L) 3.8-8.6 6.40 (5.31-8.02) 6.35 (5.40-7.93) .792 
ANC (x 109/L) 2.1-6.1 3.81 (2.94-5.07) 3.81 (2.96-5.17) .437 
Neutrophil (%) 40-77 59.80 (53.45-65.68) 59.60 (54.65-65.35) .975 
ALC (x 109/L) 1.3-3.5 1.92 (1.51-2.32) 1.87 (1.57-2.25) .722 
Lymphocyte (%) 16-44 29.20 (23.75-36.05) 30.10 (24.80-34.95) .279 
NLR  2.07 (1.50-2.75) 2.01 (1.62-2.70) .558 
Platelet (x 109/L) 140-360 320.00 (261.50-378.00) 272.00 (231.50-331.50) < .001 
MPV (fL) 7-9 8.40 (7.75-9.20) 8.80 (7.98-9.63) < .001 
PDW (%)  37.30 (18.20-51.15) 18.30 (15.65-39.00) < .001 
PCT (%)  0.27 (0.22-0.32) 0.24 (0.20-0.29) < .001 
PLR  170.63 (134.58-222.89) 140.32 (116.42-182.42) < .001 
Iron (µg/dL) 60-170 23.00 (14.00-42.25) 65.00 (42.00-86.50) < .001 
TIBC (µmol/L) 250-450 393.00 (346.50-437.00) 349.00 (304.75-377.75) < .001 
Tfsat (%)  6.00 (3.40-10.60) 18.85 (12.93-26.70) < .001 
Ferritin (ng/mL) 20-300 5.75 (2.70-10.63) 31.50 (26.30-45.05) < .001 
Abbreviations: IQR: interquartile range; MCV: mean corpuscular volume; RDW: red cell distribution width; MCH: mean cell hemoglobin; MCHC: mean cell 
hemoglobin concentration; WBC: white blood cell; ANC: absolute neutrophil count; ALC: absolute lymphocyte count; NLR: neutophil/lymphocyte ratio; MPV: mean 
platelet volume; PDW: platelet distribution width; PCT: platelet crit; PLR: platelet/lymphocyte ratio; TIBC: total iron binding capacity; Tfsat: transferrin saturation.  
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2. Complete Blood Count & Iron Parameters 
White blood cell (WBC) count, absolute neutrophil 
count, neutrophil percent, absolute lymphocyte count, 
lymphocyte percent, and NLR did not significantly differ 
before and after IDA treatment. However, there was a 
statistically difference between all other hematologic 
parameters including iron metabolism and platelets 
before and after the treatment of IDA (Table 1). 
NLR 
NLR values did not differ significantly in terms of 
IDA treatment (2.07 vs. 2.01, p= .558; Figure 1). 
 
Figure 1: Neutrophil to lymphocyte ratio (NLR) before and 
after the treatment of iron deficiency anemia (IDA) is shown 
by box plots. NLR did not differ significantly in terms of IDA 
treatment (p= .558). 
PLR 
PLR levels were significantly decreased after IDA 
treatment (170.63 vs. 140.32, p< .001; Figure 2). 
 
Figure 2: Platelet to lymphocyte ratio (PLR) before and after 
the treatment of iron deficiency anemia (IDA) is shown by box 
plots. PLR decreased significantly after IDA treatment (p< 
.001). 
Iron Metabolism Parameters 
Serum iron, Tfsat, and ferritin levels were 
significantly increased; whereas serum TIBC levels 
were significantly decreased after the treatment of IDA 
(Table 1).  
Platelets and Related Parameters 
Platelet counts, PDW, and PCT were significantly 
decreased; whereas MPV was significantly increased 
after IDA treatment (Table 1).  
3. Correlation Analyses 
NLR 
Correlation analyses between pre-treatment NLR 
and pre-treatment iron parameters were calculated. A 
low-unremarkable inverse correlation between NLR, 
and serum iron (p= .024) and Tfsat (p= .038) was 
observed; whereas there was no correlation between 
NLR, and TIBC or ferritin levels (Table 2). The NLR 
and PLR were positively correlated either before (r= 
.547; p= .01) or after (r= .460; p= .01) the treatment of 
IDA. 
Table 2: Spearman’s Coefficients (r) between NLR and 
Iron Parameters 
Parameters Spearman Coefficient p-Value 
Iron (µg/dL) -0.163 0.024 
TIBC (µmol/L) -0.082 0.258 
Tfsat (%) -0.151 0.038 
Ferritin (ng/mL) 0.140 0.052 
Abbreviations= TIBC: total transferrin binding capacity; Tfsat: transferrin 
saturation 
PLR 
Correlation analyses between pre-treatment PLR 
and pre-treatment iron parameters were calculated. A 
low-unremarkable inverse correlation between PLR, 
and serum iron (p= .002) and Tfsat (p= .013) was 
observed; whereas there was no correlation between 
PLR, and TIBC or ferritin levels (Table 3). 
Table 3: Spearman’s Coefficients (r) between PLR and 
Iron Parameters 
Parameters Spearman Coefficient p-Value 
Iron (µg/dL) -0.226 0.002 
TIBC (µmol/L) -0.113 0.121 
Tfsat (%) -0.180 0.013 
Ferritin (ng/mL) -0.094 0.199 
Abbreviations= TIBC: total transferrin binding capacity; Tfsat: transferrin 
saturation 
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DISCUSSION 
Since anemia is associated with hypoxia and 
ischemia, it may affect WBCs via increasing vascular 
reactivity to catecholamine through glucocorticoids [7]. 
Singh et al. has presented that in a very small cohort 
(n= 20) with nutritional anemia, total leukocyte count 
was found to be insignificantly higher in anemic 
patients compared to those of controls. On differential 
count of leukocytes, there was increment in neutrophils 
without alteration in lymphocytes. Additionally, NLR 
was significantly (p< .001) higher in anemic vs healthy 
subjects, and platelet count was decreased in anemic 
patients [8]. In a Turkish pediatric study, focused on 
iron-deficient children with a mean age of 13.8, the 
percentage of neutrophils with stimulated oxidative 
burst activity was found to be significantly lower than 
those of healthy controls. In addition, although the 
difference is borderline and not significant, the ratio of 
neutrophils with phagocytic activity was also lower in 
the anemic group [9]. In iron deficient pediatric patients 
T lymphocytes, CD4+ T-cells, and the CD4:CD8 ratio 
were all significantly lower than those noted in healthy 
children. Iron replation was associated with significantly 
improved CD4+ cell counts [10]. Therefore, not only the 
quantitative properties of neutrophils, but also 
qualitative aspects of neutrophils may be associated 
with inflammatory response in iron deficiency. The 
present study was carried out in 200 patients with IDA. 
Either total or differential leukocyte counts (neutrophils, 
lymphocytes) were in normal ranges, and we also did 
not observe any significant alterations in NLR after the 
treatment of IDA. Pre-treatment platelet parameters 
were all in normal ranges except PDW, and PDW was 
found to be higher in patients with IDA according to 
normal reference values. Platelet counts, PLR, PDW, 
and PCT were significantly decreased; whereas MPV 
was significantly increased after the treatment of IDA 
(Table 1).  
A high NLR is related with an adverse outcome in 
many solid tumors. Most recently, in a systematic 
meta-analysis including 100 studies with a total of 
40,559 patients, it has been suggested that a high NLR 
may reflect either greater tumor burden or a more 
prolonged chronic inflammatory process [4]. Although 
the exact mechanism about the prognostic role of NLR 
in subjects with cancer remains unclear, most studies 
have pointed out a potential and/or possible 
association between a high NLR and inflammation [4]. 
Several inflammatory cytokines (especially IL-6) and 
chemokines released by both the cancer cells and 
associated host cells (i.e. neutrophis) [11, 12] may 
trigger a “cytokine storm” like process and eventually 
contribute to a systemic inflammatory response. 
Additionally, it has also been suggested that NLR may 
also correlate with non-cancer conditions including, 
myocardial ischemic events [13], acute pancreatitis [3], 
or inflammatory bowel diseases [14]. As well as NLR, 
an increased PLR is also indicative of an increased 
host inflammatory response [15]. In the present paper, 
PLR decreased significantly with the improvement of 
IDA; but NLR did not differ significantly after IDA 
treatment.  
Platelets are known to be active players in the 
induction of inflammatory response, in addition to their 
participation in hemostasis [16, 17]. In contrast to acute 
infections with viruses or bacteria, chronic inflammation 
is often related with increased megakaryopoiesis and 
reactive thrombocytosis [17]. Iron deficiency (ID) is a 
recognized cause of reactive thrombocytosis even 
outside the setting of inflammation [18, 19]. However, 
the exact mechanism of thrombocytosis in ID is not yet 
clear. Interleukin (IL) 6 plays a key role in the systemic 
inflammatory response and thrombocytosis by several 
mechanisms including; increasing the synthesis of 
acute phase proteins such as C-reactive protein (CRP), 
serum amyloid A protein, and/or fibrinogen [20], 
decreasing albumin biosynthesis in the liver [20], 
stimulating human megakaryocytic proliferation and 
differentiation synergistically with IL-3 [21], and 
stimulating thrombopoietin production [17]. Contrastly, 
in an animal iron-deficieny model, Evstatiev et al. have 
recently showed that ID did not alter the production of 
hematopoeitic growth factors including thrombopoietin, 
IL-6 or IL-11 [22]. In the present analysis, pre-treatment 
platelet counts were significantly higher than the post-
treatment platelet counts (even both of them were 
within normal reference ranges) which can, at least 
partly, be explained by a “relative” reactive 
thrombocytosis induced by IDA. The improvement of 
this reactive thrombocytosis after iron replacement 
without an alteration in lymphocytes, gave rise to a 
significant decrease in PLR.  
A small peptide called “hepcidin” has a crucial role 
in the control of iron availability to tissues. Hepcidin 
expression is upregulated by inflammation. IDA is 
frequently associated with anemia of chronic diseases, 
including chronic heart failure, cancer, chronic kidney 
disease, rheumatoid arthritis, obesity, and inflammatory 
bowel diseases [23]. It has also been shown that IL-6 
enhances the synthesis of hepcidin in the liver which 
regulates iron recycling, resulting in anemia due to 
hypofferemia [20, 24].  
This study had some limitations. Firstly, other 
markers of systemic inflammation such as CRP, or 
hypoalbuminemia should be obtained in order to 
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compare them with NLR and PLR by multivariate 
analyses. Second, we were not able to determine the 
aforementioned hematopoieitic growth factors or the 
master regulator of iron homeostasis, hepcidin. Despite 
these factors, our study may help to better understand 
the inflammatory aspects of iron deficiency anemia by 
clinicians. Further prospectively designed studies with 
more patients are needed in order to elucidate the 
association of inflammation and IDA. 
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